Related Experiment Video
Updated: Jul 15, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Development of device therapy for ventricular arrhythmias
1Department of Medical and Molecular Biosciences, University of Technology, Sydney, PO Box 123, Broadway, NSW 2007, Australia. Loraine.Holley@uts.edu.au
Implantable cardioverter defibrillators are now the primary treatment for ventricular arrhythmias. Advances in technology have improved their effectiveness and patient acceptance, enhancing quality of life and survival for heart failure patients.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- The implantable cardioverter defibrillator (ICD) has become the preferred treatment for ventricular arrhythmias over the last 25 years.
- Research has focused on understanding the complex mechanisms of ventricular arrhythmias and defibrillation.
Observation:
- Significant advancements in capacitor and battery technologies have been made.
- Improvements in arrhythmia discrimination, pacing algorithms, shock waveforms, and monitoring capabilities have enhanced device functionality.
Findings:
- These technological improvements have led to wider adoption and increased patient acceptance of ICDs.
- The integration of cardiac resynchronisation therapy with ICDs offers improved quality of life and survival for heart failure patients.
Implications:
- The evolution of heart failure treatment has been significantly influenced by the development and application of ICDs.
- Further research into ICDs may uncover new insights into the progression and management of heart failure.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Cardiomyopathy V: Interprofessional Care
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure VI: Adjunct Therapies
